Evidence map›Paper›PMID 28340322›Full record

Trial reportHuman vaccines & immunotherapeutics2017

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.

Timo Vesikari, Luis Rivera, Tiina Korhonen, Anitta Ahonen, Brigitte Cheuvart, Marjan Hezareh, Winnie Janssens, Narcisa Mesaros

2 registry-linked trialsOpen access · hybridAbstract readClinical Trial, Phase IClinical Trial, Phase IIComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01248884 phase2completednot on this map

Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) in Primary Infant Vaccination

TypeinterventionalSponsorGlaxoSmithKlineRan2010 to 2012Enrolled721ConditionsTetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type bArmsInfanrix hexa™, Prevenar 13®, GSK217744
NCT01453998 phase2completednot on this map

Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)

TypeinterventionalSponsorGlaxoSmithKlineRan2011 to 2012Enrolled657ConditionsAcellular Pertussis, Hepatitis B, Haemophilus Influenzae Type b, TetanusArmsInfanrix hexa, Prevenar 13, GSK217744
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Timo Vesikaria Vaccine Research Center , University of Tampere , Tampere , Finland.
Luis Riverab Hospital Maternidad Nuestra Señora de la Altagracia Santo Domingo , Santo Domingo , Dominican Republic.
Tiina Korhonenc University of Tampere, Tampere Vaccine Research Clinic , Tampere , Finland.
Anitta Ahonend Vaccine Research Center , University of Tampere, Järvenpää Vaccine Clinic , Järvenpää , Finland.
Brigitte Cheuvarte GSK , Wavre , Belgium.
Marjan Hezarehf Chiltern International c/o GSK , Wavre , Belgium.
Winnie Janssensg GSK , Wavre , Belgium.
Narcisa Mesarosg GSK , Wavre , Belgium.
GlaxoSmithKline (Belgium) · BETampere University · FIThe Chiltern Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Safety and immunogenicity of 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens of the combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Hib vaccine (DTPa-HBV-IPV/Hib) were evaluated in a Primary (NCT01248884) and a Booster vaccination (NCT01453998) study. In the Primary study, 721 healthy infants (randomized 1:1:1) received 3 doses of DTPa-HBV-IPV/Hib formulation A (D

Indexed as

Antibodies, BacterialAntibodies, ViralDiphtheria-Tetanus-Pertussis VaccineDouble-Blind MethodDrug-Related Side Effects and Adverse ReactionsFemaleFeverHaemophilus VaccinesHepatitis B VaccinesHumansImmunization ScheduleInfantMalePoliovirus Vaccine, InactivatedVaccines, CombinedAntibodies, BacterialAntibodies, Viraldiphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccineDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesHepatitis B VaccinesPoliovirus Vaccine, InactivatedVaccines, Combinedacellular pertussisdiphtheriaDTPa-HBV-IPV/HibHaemophilus influenzae type bhepatitis Bimmunogenicityinfantspoliovirussafetytetanus

Identifiers

PMID28340322
PMCPMC5512790
OpenAlexW2597614229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.